A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 7, 2013, Pages 1040-1045

  Gergis, Usama ^a   Roboz, Gail ^a   Shore, Tsiporah ^a   Ritchie, Ellen ^a   Mayer, Sebastian ^a   Wissa, Usama ^a   McKenna, Marshall ^a   Christos, Paul ^a   Pearse, Roger ^a   Mark, Tomer ^a   Scandura, Joseph ^a   van Besien, Koen ^a   Feldman, Eric ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acute myelogenous leukemia transplantation; CPX 351; Fludarabine busulfan; Refractory leukemia

Indexed keywords

BUSULFAN; COTRIMOXAZOLE; CPX 351; CYTARABINE; DAUNORUBICIN; FLUCONAZOLE; FLUDARABINE; METHOTREXATE; TACROLIMUS; UNCLASSIFIED DRUG; VALACICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BRAIN TUMOR; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG FORMULATION; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HUMAN; IRON OVERLOAD; KARNOFSKY PERFORMANCE STATUS; LEUKEMIA RELAPSE; LIVER FAILURE; MALE; MAXIMUM TOLERATED DOSE; MORTALITY; MUCOSA INFLAMMATION; NEUTROPHIL; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; REDUCED INTENSITY CONDITIONING; REFRACTORY ACUTE LEUKEMIA; SEPSIS; THROMBOCYTE; TREATMENT RESPONSE;

ADULT; AGED; BUSULFAN; CASE-CONTROL STUDIES; CYTARABINE; DAUNORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84879400160     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.04.013     Document Type: Article

References (25)

1. Estey E., Thall P., David C. Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 1997, 40(Suppl):S9-S12.
2. Ravandi F., Cortes J., Faderl S., et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 2010, 116:5818-5823.
3. Breems D.A., Van Putten W.L., Huijgens P.C., et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. JClin Oncol 2005, 23:1969-1978.
4. Chevallier P., Labopin M., Turlure P., et al. Anew leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia 2011, 25:939-944.
5. Duval M., Klein J.P., He W., et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. JClin Oncol 2010, 28:3730-3738.
6. Schmid C., Schleuning M., Schwerdtfeger R., et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006, 108:1092-1099.
7. Liu Q.F., Fan Z.P., Zhang Y., et al. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant 2009, 15:1376-1385.
8. Locke F.L., Artz A., Rich E., et al. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant 2010, 45:1692-1698.
9. Bayne W.F., Mayer L.D., Swenson C.E. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. JPharm Sci 2009, 98:2540-2548.
10. Dicko A., Kwak S., Frazier A.A., et al. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int J Pharm 2010, 391:248-259.
11. Kim H.P., Gerhard B., Harasym T.O., et al. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol 2011, 39:741-750.
12. Lim W.S., Tardi P.G., Dos Santos N., et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res 2010, 34:1214-1223.
13. Lim W.S., Tardi P.G., Xie X., et al. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. Leuk Lymphoma 2010, 51:1536-1542.
14. Tardi P., Johnstone S., Harasym N., et al. Invivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009, 33:129-139.
15. Feldman E.J., Lancet J.E., Kolitz J.E., et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. JClin Oncol 2011, 29:979-985.
16. Lancet JE, Cortes JE, Hogge DE, etal. Phase 2B randomized study of CPX-351 vs. cytarabine (CYT)+ daunorubicin (DNR) (7+ 3 regimen) in newly diagnosed AML patients aged 60-75. ASH Annual Meeting Abstracts 2010;116:655.
17. Bearman S.I., Appelbaum F.R., Buckner C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. JClin Oncol 1988, 6:1562-1568.
18. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. JClin Oncol 2003, 21:4642-4649.
19. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
20. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
21. Santos F.P., Jones D., Qiao W., et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer 2011, 117:2145-2155.
22. Gochee P.A., Powell L.W., Cullen D.J., et al. Apopulation-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002, 122:646-651.
23. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose- and schedule-finding study. Cancer 2010, 116:5420-5431.
24. Sharma M., Ravandi F., Bayraktar U.D., et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant 2011, 17:1874-1877.
25. Ding L., Ley T.J., Larson D.E., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.